Nilotinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Nilotinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Bcr-Abl Tyrosine Kinase Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2C8 Inducers. DrugCentral lists 82 molecular targets, including ABL1|BCR, DDR1 and ABL1. Recorded indications include Chronic Myelocytic Leukemia Accelerated Phase, Chronic phase chronic myeloid leukemia and Philadelphia Chromosome Positive Chronic Myelocytic Leukemia.

• Approval status: onp (first approved 2007 by the FDA).
• Drug class: Kinase Inhibitor.
• Mechanism of action: Bcr-Abl Tyrosine Kinase Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2C8 Inducers.
• Molecular targets: ABL1|BCR, DDR1, ABL1 and CA2 (82 listed in DrugCentral).
• Indications: Chronic Myelocytic Leukemia Accelerated Phase, Chronic phase chronic myeloid leukemia and Philadelphia Chromosome Positive Chronic Myelocytic Leukemia.
• ATC code: L01EA03 (BCR-ABL tyrosine kinase inhibitors).
• Molecular formula: C28H22F3N7O; molecular weight 529.53 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Chronic Myelocytic Leukemia Accelerated Phase
• Chronic phase chronic myeloid leukemia
• Philadelphia Chromosome Positive Chronic Myelocytic Leukemia

Contraindications (24)

• Anemia
• Breastfeeding (mother)
• Congenital long QT syndrome
• Diabetes mellitus
• Disease of liver
• Elevated Serum Lipase
• Gastrectomy
• Hyperbilirubinemia
• Hypercholesterolemia
• Hyperglycemia
• Hyperkalemia
• Hypertensive disorder
• Hypocalcemia
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypophosphatemia
• Liver function tests abnormal
• Neutropenic disorder
• Pancreatitis
• Pregnancy, function
• Prolonged QT interval
• Thrombocytopenic disorder
• Torsades de pointes

Mechanism & targets

• Mechanism of action (MoA): Bcr-Abl Tyrosine Kinase Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2C8 Inducers; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; P-Glycoprotein Inhibitors; UGT1A1 Inhibitors
• Established pharmacologic class: Kinase Inhibitor

Molecular targets (82)

Target	Gene	Action	Activity
Bcr/Abl fusion protein	ABL1|BCR	unknown	IC50 9.48
Epithelial discoidin domain-containing receptor 1	DDR1	unknown	Kd 8.96
Tyrosine-protein kinase ABL1	ABL1	inhibitor	Kd 8.44
Carbonic anhydrase 2	CA2	unknown	Ki 8.39
Discoidin domain-containing receptor 2	DDR2	unknown	Kd 8.22
Mitogen-activated protein kinase kinase kinase MLT	ZAK	unknown	Kd 7.96
Platelet-derived growth factor receptor beta	PDGFRB	unknown	Kd 7.80
Mast/stem cell growth factor receptor Kit	KIT	unknown	Kd 7.77
Integrin-linked protein kinase	ILK	unknown	Kd 7.70
Abelson tyrosine-protein kinase 2	ABL2	unknown	Kd 7.59
Carbonic anhydrase 1	CA1	unknown	Ki 7.53
Mitogen-activated protein kinase 11	MAPK11	unknown	Kd 7.44
Ephrin type-A receptor 8	EPHA8	unknown	Kd 7.43
Carbonic anhydrase 9	CA9	unknown	Ki 7.38
Macrophage colony-stimulating factor 1 receptor	CSF1R	unknown	Kd 7.35
Tyrosine-protein kinase Lck	LCK	unknown	Kd 7.33
Platelet-derived growth factor receptor alpha	PDGFRA	unknown	Kd 7.13
Carbonic anhydrase 15	Ca15	unknown	Ki 7.10
Tyrosine-protein kinase FRK	FRK	unknown	Kd 7.07
Tyrosine-protein kinase Lyn	LYN	unknown	Kd 7.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-10-29	FDA	—	NOVARTIS	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01EA03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › BCR-ABL tyrosine kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ABL1, BCR · Testing Required
• FDA label: ABL1, BCR · Testing Required
• FDA label: UGT1A1 · Informative PGx
• HCSC label: UGT1A1 · Actionable PGx
• HCSC label: ABL1, BCR · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cytogenetic analysis abnormal	1257.0
Electrocardiogram QT prolonged	978.2
Peripheral arterial occlusive disease	881.2
Blast crisis in myelogenous leukaemia	819.8
Second primary malignancy	714.6
Drug resistance	658.8
Pleural effusion	592.1
Myocardial infarction	535.3
Amaurosis fugax	507.0
Philadelphia chromosome positive	461.9
Lipase increased	438.5
Off label use	434.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nilotinib is on its molecule page.

• Molecular formula: C₂₈H₂₂F₃N₇O
• Molecular weight: 529.53 g/mol
• CAS number: —
• InChIKey: HHZIURLSWUIHRB-UHFFFAOYSA-N
• PubChem CID: 644241

CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nilotinib used for?

DrugCentral lists the following indications for Nilotinib: Chronic Myelocytic Leukemia Accelerated Phase, Chronic phase chronic myeloid leukemia and Philadelphia Chromosome Positive Chronic Myelocytic Leukemia.

How does Nilotinib work?

Nilotinib is classified as Bcr-Abl Tyrosine Kinase Inhibitors, Cytochrome P450 2B6 Inducers and Cytochrome P450 2C8 Inducers; its molecular targets in DrugCentral include ABL1|BCR, DDR1, ABL1 (inhibitor) and CA2.

When was Nilotinib first approved?

Nilotinib was first approved by the FDA in 2007.

What drug class does Nilotinib belong to?

Nilotinib is in the Kinase Inhibitor class.

What is the chemical formula of Nilotinib?

Nilotinib has the molecular formula C28H22F3N7O and a molecular weight of 529.53 g/mol.

Sources

• DrugCentral drug card 1932 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201740 — compound record and bioactivity
• PubChem CID 644241 — chemical identifiers
• DrugBank DB04868 — drug record
• FDA UNII F41401512X — substance identity
• DailyMed: FDA labels for Nilotinib — current prescribing information (label search)
• UniProt Q08345 (DDR1) — target protein
• UniProt P00519 (ABL1) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt Q16832 (DDR2) — target protein
• UniProt Q9NYL2 (ZAK) — target protein
• UniProt P09619 (PDGFRB) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.